Q linea AB - Asset Resilience Ratio

Latest as of December 2025: 69.82%

Q linea AB (QLINEA) has an Asset Resilience Ratio of 69.82% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Q linea AB (QLINEA) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

Skr258.11 Million
≈ $27.78 Million USD Cash + Short-term Investments

Total Assets

Skr369.67 Million
≈ $39.78 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Q linea AB's Asset Resilience Ratio has changed over time. See how leveraged is Q linea AB's balance sheet to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Q linea AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Q linea AB (QLINEA) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr258.11 Million 69.82%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr258.11 Million 69.82%

Asset Resilience Insights

  • Very High Liquidity: Q linea AB maintains exceptional liquid asset reserves at 69.82% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Q linea AB Industry Peers by Asset Resilience Ratio

Compare Q linea AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Medacta Group SA
SW:MOVE
Medical Devices 0.86%
Double Medical Technology Inc
SHE:002901
Medical Devices 12.59%
Shenzhen New Industries Biomedical
SHE:300832
Medical Devices 9.95%
Jafron Biomedical Co Ltd
SHE:300529
Medical Devices 39.15%
Sinocare Inc
SHE:300298
Medical Devices 3.53%
Xiangyu Medical Co. Ltd. A
SHG:688626
Medical Devices 1.53%
INKON Life Technology Co Ltd
SHE:300143
Medical Devices 5.73%
HOB Biotech Group Corp Ltd
SHG:688656
Medical Devices 2.62%

Annual Asset Resilience Ratio for Q linea AB (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Q linea AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 69.82% Skr258.11 Million
≈ $27.78 Million
Skr369.67 Million
≈ $39.78 Million
+52.48pp
2024-12-31 17.34% Skr25.66 Million
≈ $2.76 Million
Skr147.99 Million
≈ $15.93 Million
-17.98pp
2023-12-31 35.33% Skr81.95 Million
≈ $8.82 Million
Skr231.98 Million
≈ $24.96 Million
+0.08pp
2022-12-31 35.24% Skr73.09 Million
≈ $7.87 Million
Skr207.39 Million
≈ $22.32 Million
-0.34pp
2021-12-31 35.58% Skr166.03 Million
≈ $17.87 Million
Skr466.63 Million
≈ $50.22 Million
-38.86pp
2020-12-31 74.45% Skr306.89 Million
≈ $33.03 Million
Skr412.23 Million
≈ $44.36 Million
+19.30pp
2019-12-31 55.15% Skr206.48 Million
≈ $22.22 Million
Skr374.41 Million
≈ $40.29 Million
-38.43pp
2018-12-31 93.58% Skr504.44 Million
≈ $54.29 Million
Skr539.07 Million
≈ $58.01 Million
+57.77pp
2017-12-31 35.81% Skr6.59 Million
≈ $708.97K
Skr18.40 Million
≈ $1.98 Million
--
pp = percentage points

About Q linea AB

ST:QLINEA Sweden Medical Devices
Market Cap
$35.38 Million
Skr328.76 Million SEK
Market Cap Rank
#23242 Global
#441 in Sweden
Share Price
Skr17.35
Change (1 day)
-5.19%
52-Week Range
Skr0.05 - Skr61.00
All Time High
Skr176.50
About

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disp… Read more